ARTICLE | Tools & Techniques

Letting go of inhibition

April 12, 2012 7:00 AM UTC

A University of California, San Francisco team has created a new class of reversible, covalent small molecule kinase inhibitors that could be more selective and safer than previous kinase inhibitors.1 Principia Biopharma Inc. has exclusively licensed the technology and plans to develop new compounds to treat cancer and autoimmune diseases.

Many first-generation kinase inhibitors hit multiple kinases in addition to the kinase implicated in disease, which often results in unwanted off-target effects...